Advertisement

Medical Oncology

, 36:18 | Cite as

The timing of docetaxel initiation in metastatic castrate-sensitive prostate cancer and the rate of chemotherapy-induced toxicity

  • Igal KushnirEmail author
  • Kim Koczka
  • Michael Ong
  • Christina Canil
  • Dominick Bossé
  • Elham Sabri
  • M.Neil Reaume
Original Paper
  • 62 Downloads

Abstract

Docetaxel pharmacokinetics are affected by androgen deprivation therapy (ADT), which is attributed to changes in liver metabolism induced by castration. In this retrospective analysis, we assessed whether initiating docetaxel treatment in close proximity to the start of ADT therapy for metastatic castrate-sensitive prostate cancer (mCSPC) is associated with more treatment-related toxicity. We identified all patients with mCSPC treated at The Ottawa Hospital that received docetaxel chemotherapy between June 2014 and September 2017. For each patient, we calculated the time to chemotherapy (TTC) interval between the start of ADT and the first cycle of docetaxel. We checked for an association between TTC and febrile neutropenia (FN), toxicity-induced dose reduction, toxicity-induced treatment delay, and toxicity-induced treatment discontinuation. Eighty-three patients were identified. The median TTC was 67 days (range 3–189). Twenty-three patients (27.7%) experienced FN. Docetaxel toxicity resulted in 8 patients (9.6%) having their treatment delayed, 30 patients (36.1%) having their dose reduced and 18 (21.6%) having their treatment discontinued before completing the scheduled 6 cycles. No correlation was found between the TTC and FN (P = 0.99), docetaxel dose reduction (P = 0.95), treatment delay (P = 0.06), and treatment discontinuation (P = 0.88). The timing of docetaxel treatment initiation in relation to ADT initiation in patients with mCSPC did not affect the rate of treatment-related toxicity. Therefore, there is no indication for upfront chemotherapy delay from start of ADT unless clinical factors warrant a delay in starting chemotherapy. A higher than expected FN rate was identified, and primary prophylaxis should be considered.

Keywords

Prostate cancer Castrate-sensitive Docetaxel Toxicity 

Notes

Funding

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Compliance with ethical standards

Conflict of interest

CC declared: Honorarium—Janssen; Advisory boards—Roche, Ipsen, Pfizer, Eisai, Merk, EMD Serono, Bayer, BMS, AstraZeneca, Janssen; Travel support—Sanofi, Amgen, Pfizer; Research funding – Eisai. DB declared: Advisory/honorarium—BMS, Pfizer, AbbVie, and AstraZenaca. NMR declared: Honoraria—Astellas, Novartis, Janssen, Roche, Pfizer, AstraZeneca. IK, KK, MO, ES declare no conflict of interest associated with this publication.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

Informal consent

For this retrospective study formal consent was not required by the Ottawa Health Science Network Research Ethics Board.

References

  1. 1.
    Tannock IF, deWit R, Berry WR, Horti J, Pluzanska A, Chi KN, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351:1502–12.CrossRefGoogle Scholar
  2. 2.
    James ND, Sydes MR, Clarke NW, Mason MD, Dearnaley DP, Spears MR, et al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet. 2016;387:1163–77.CrossRefGoogle Scholar
  3. 3.
    Sweeney CJ, Chen YH, Carducci M, Liu G, Jarrard DF, Eisenberger M, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med. 2015;373:737–46.CrossRefGoogle Scholar
  4. 4.
    Tucci M, Bertaglia V, Vignani F, Buttigliero C, Fiori C, Porpiglia F, et al. Addition of docetaxel to androgen deprivation therapy for patients with hormone-sensitive metastatic prostate cancer: a systematic review and meta-analysis. Eur Urol. 2016;69:563–73.CrossRefGoogle Scholar
  5. 5.
    Franke RM, Carducci MA, Rudek MA, Baker SD, Sparreboom A. Castration-dependent pharmacokinetics of docetaxel in patients with prostate cancer. J Clin Oncol. 2010;28:4562–7.CrossRefGoogle Scholar
  6. 6.
    Bruno R, Vivier N, Veyrat-Follet C, Montay G, Rhodes GR. Population pharmacokinetics and pharmacokinetic–pharmacodynamic relationships for docetaxel. Invest New Drugs. 2001;19:163–9.CrossRefGoogle Scholar
  7. 7.
    Mahil J, Hughes C, Patel K, Lyons J, Elliott PA, Choudhury A, et al. Febrile neutropenia rates in men treated with docetaxel chemotherapy for metastatic hormone-sensitive prostate cancer. Clin Oncol (R Coll Radiol). 2016;28:612.CrossRefGoogle Scholar
  8. 8.
    Tsao CK, Galsky MD, Oh WK. Docetaxel for metastatic hormone-sensitive prostate cancer: urgent need to minimize the risk of neutropenic fever. Eur Urol. 2016;70:707–8.CrossRefGoogle Scholar
  9. 9.
    Templeton AJ, Vera-Badillo FE, Wang L, Attalla M, DeGouveia P, Leibowitz-Amit R, et al. Translating clinical trials to clinical practice: outcomes of men with metastatic castration resistant prostate cancer treated with docetaxel and prednisone in and out of clinical trials. Ann Oncol. 2013;24:2972–7.CrossRefGoogle Scholar
  10. 10.
    Rulach RJ, McKay S, Neilson S, White L, Wallace J, Carruthers R, et al. Real-world uptake, safety profile and outcomes of docetaxel in newly diagnosed metastatic prostate cancer. BJU Int. 2018;121:268–74.CrossRefGoogle Scholar
  11. 11.
    Vogel CL, Wojtukiewicz MZ, Carroll RR, Tjulandin SA, Barajas-Figueroa LJ, Wiens BL, et al. First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study. J Clin Oncol. 2005;23:1178–84.CrossRefGoogle Scholar
  12. 12.
    Aapro MS, Bohlius J, Cameron DA, Dal Lago L, Donnelly JP, Kearney N, et al. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer. 2011;47:8–32.CrossRefGoogle Scholar
  13. 13.
    Smith TJ, Bohlke K, Lyman GH, Carson KR, Crawford J, CrossS J, et al. Recommendations for the use of WBC growth factors: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2015;33:3199–212.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.The Ottawa Hospital Cancer CentreUniversity of OttawaOttawaCanada
  2. 2.Sackler Faculty of MedicineTel Aviv UniversityTel AvivIsrael
  3. 3.Ottawa Hospital Research InstituteOttawaCanada

Personalised recommendations